ADVERTISEMENT

Conference Report

ASCO 2022 – Hope SHINEs for elderly patients with mantle cell lymphoma

Elena Riboldi — Agenzia Zoe   |   07 June 2022

Takeaway

  • In elderly patients with newly diagnosed mantle cell lymphoma (MCL), the addition of ibrutinib to standard-of-care chemoimmunotherapy (bendamustine-rituximab, BR) and rituximab maintenance significantly improved progression free survival (PFS).

 

Why this matters

  • MCL is often diagnosed in people aged 65 years or over.
  • Outcomes of MCL are greatly unsatisfactory...

          

November Challenge

Ends in 1d 5h
left
right

Topic Challenges

left
right